CN108697710B - 作为nik抑制剂的新颖的经取代的氰基吲哚啉衍生物 - Google Patents

作为nik抑制剂的新颖的经取代的氰基吲哚啉衍生物 Download PDF

Info

Publication number
CN108697710B
CN108697710B CN201780007786.1A CN201780007786A CN108697710B CN 108697710 B CN108697710 B CN 108697710B CN 201780007786 A CN201780007786 A CN 201780007786A CN 108697710 B CN108697710 B CN 108697710B
Authority
CN
China
Prior art keywords
group
alkyl
het
substituted
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780007786.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN108697710A (zh
Inventor
I·斯坦斯菲尔德
O·A·G·奎伊罗勒
V·S·邦塞勒特
格哈德·马克斯·格罗斯
埃德加·雅各比
L·米尔波尔
J·J·库拉戈维斯基
C·马克勒奥德
S·E·马恩
西蒙·理查德·格林
G·海恩德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN108697710A publication Critical patent/CN108697710A/zh
Application granted granted Critical
Publication of CN108697710B publication Critical patent/CN108697710B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/535—Organo-phosphoranes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201780007786.1A 2016-01-22 2017-01-20 作为nik抑制剂的新颖的经取代的氰基吲哚啉衍生物 Active CN108697710B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16152416.0 2016-01-22
EP16152416 2016-01-22
EP16159651 2016-03-10
EP16159651.5 2016-03-10
PCT/EP2017/051150 WO2017125530A1 (en) 2016-01-22 2017-01-20 New substituted cyanoindoline derivatives as nik inhibitors

Publications (2)

Publication Number Publication Date
CN108697710A CN108697710A (zh) 2018-10-23
CN108697710B true CN108697710B (zh) 2022-02-18

Family

ID=57868252

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780007786.1A Active CN108697710B (zh) 2016-01-22 2017-01-20 作为nik抑制剂的新颖的经取代的氰基吲哚啉衍生物

Country Status (20)

Country Link
US (1) US11180487B2 (cg-RX-API-DMAC7.html)
EP (1) EP3405196B1 (cg-RX-API-DMAC7.html)
JP (1) JP6910359B2 (cg-RX-API-DMAC7.html)
KR (1) KR102784966B1 (cg-RX-API-DMAC7.html)
CN (1) CN108697710B (cg-RX-API-DMAC7.html)
AU (1) AU2017209935B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018014675B1 (cg-RX-API-DMAC7.html)
CA (1) CA3011880A1 (cg-RX-API-DMAC7.html)
DK (1) DK3405196T3 (cg-RX-API-DMAC7.html)
ES (1) ES2775449T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20200133T1 (cg-RX-API-DMAC7.html)
HU (1) HUE047684T2 (cg-RX-API-DMAC7.html)
IL (1) IL260500B (cg-RX-API-DMAC7.html)
LT (1) LT3405196T (cg-RX-API-DMAC7.html)
MX (1) MX2018008974A (cg-RX-API-DMAC7.html)
PH (1) PH12018501567A1 (cg-RX-API-DMAC7.html)
SI (1) SI3405196T1 (cg-RX-API-DMAC7.html)
TW (1) TWI739783B (cg-RX-API-DMAC7.html)
WO (1) WO2017125530A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201804688B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3405464B1 (en) 2016-01-22 2019-12-04 Janssen Pharmaceutica NV New 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors
HRP20200133T1 (hr) 2016-01-22 2020-05-15 Janssen Pharmaceutica Nv Novi supstituirani derivati cijanoindolina kao inhibitori nik
WO2018002219A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Cyanoindoline derivatives as nik inhibitors
EP3478675B1 (en) 2016-06-30 2020-04-22 Janssen Pharmaceutica NV Heteroaromatic derivatives as nik inhibitors
CN110818690B (zh) 2016-07-26 2021-08-10 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物
US11465984B2 (en) * 2017-09-30 2022-10-11 Shanghai Haihe Pharmaceutical Co., Ltd. Compound having ERK kinase inhibitory activity and use thereof
TW202045008A (zh) 2019-02-01 2020-12-16 印度商皮埃企業有限公司 4-取代的異噁唑/異噁唑啉(雜)芳基脒化合物、及其製備與用途
US20220177459A1 (en) * 2019-04-02 2022-06-09 Hinova Pharmaceuticals Inc. Aromatic amine compound and use thereof in preparation of ar and brd4 dual inhibitors and regulators
CR20210587A (es) 2019-05-31 2022-02-11 Janssen Pharmaceutica Nv Inhibidores de molécula pequeña de quinasa inductora de nf-kb
CA3182276A1 (en) 2020-05-08 2021-12-02 Halia Therapeutics, Inc. Inhibitors of nek7 kinase
EP4393508A4 (en) * 2021-08-23 2024-12-04 Osaka University COMPOSITION FOR SUPPRESSING TRANSDIFFERENTIATION OF MATURE HEPATOCYTES
WO2024059200A1 (en) 2022-09-14 2024-03-21 Halia Therapeutics, Inc. Nek7 inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009158011A1 (en) * 2008-06-26 2009-12-30 Amgen Inc. Alkynyl alcohols as kinase inhibitors
WO2010042337A1 (en) * 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02003436A (es) 1999-10-07 2002-08-20 Amgen Inc Inhibidores de triazina cinasa.
KR20030024659A (ko) 2000-02-17 2003-03-26 암겐 인코포레이티드 키나제 억제제
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
MXPA03008888A (es) 2001-03-29 2005-03-07 Vertex Pharma Inhibidores de n-terminal c-jun cinasas (jnk) y otras proteinas cinasas.
CA2450934A1 (en) 2001-06-19 2002-12-27 Marco Dodier Pyrimidine inhibitors of phosphodiesterase (pde) 7
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
NZ623069A (en) 2009-08-17 2015-11-27 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
HUE052110T2 (hu) 2010-07-29 2021-04-28 Rigel Pharmaceuticals Inc AMPK-t aktiváló heterociklusos vegyületek és alkalmazásuk
KR20140048873A (ko) 2011-04-12 2014-04-24 알츠하이머즈 인스티튜트 오브 아메리카, 인크. Ikk-관련 키나제 엡실론 및 tank 결합 키나제 1 억제제의 조성물 및 치료학적 용도
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
MX370588B (es) 2013-08-30 2019-12-16 Ptc Therapeutics Inc Inhibidores de la bmi-1 de pirimidina sustituida.
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為NIK抑制劑的新穎3-(1H-吡唑-4-基)-1H-吡咯并[2,3-c]吡啶衍生物
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作NIK抑制劑之新的1-(4-嘧啶基)-1H-吡唑並[3,2-c]吡啶衍生物
MX358346B (es) 2014-04-04 2018-08-15 Syros Pharmaceuticals Inc Inhibidores de la quinasa dependiente de ciclina 7 (cdk7).
CN106536478A (zh) 2014-05-22 2017-03-22 悉尼大学 ω‑3类似物
WO2016022645A1 (en) 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
SG11201701724VA (en) 2014-09-26 2017-04-27 Gilead Sciences Inc Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
CN106928216A (zh) * 2015-12-31 2017-07-07 中国科学院上海药物研究所 具有erk激酶抑制活性的化合物、其制备方法和用途
EP3405464B1 (en) 2016-01-22 2019-12-04 Janssen Pharmaceutica NV New 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors
HRP20200133T1 (hr) 2016-01-22 2020-05-15 Janssen Pharmaceutica Nv Novi supstituirani derivati cijanoindolina kao inhibitori nik
WO2017161028A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
EP3478675B1 (en) 2016-06-30 2020-04-22 Janssen Pharmaceutica NV Heteroaromatic derivatives as nik inhibitors
WO2018002219A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Cyanoindoline derivatives as nik inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009158011A1 (en) * 2008-06-26 2009-12-30 Amgen Inc. Alkynyl alcohols as kinase inhibitors
WO2010042337A1 (en) * 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity

Also Published As

Publication number Publication date
ES2775449T3 (es) 2020-07-27
MX2018008974A (es) 2018-11-09
KR102784966B1 (ko) 2025-03-20
PH12018501567A1 (en) 2019-01-28
EP3405196B1 (en) 2019-12-04
KR20180100441A (ko) 2018-09-10
US11180487B2 (en) 2021-11-23
HRP20200133T1 (hr) 2020-05-15
US20210087182A1 (en) 2021-03-25
WO2017125530A1 (en) 2017-07-27
SI3405196T1 (sl) 2020-03-31
LT3405196T (lt) 2020-02-25
CN108697710A (zh) 2018-10-23
ZA201804688B (en) 2022-03-30
DK3405196T3 (en) 2020-03-09
BR112018014675A2 (pt) 2018-12-11
EP3405196A1 (en) 2018-11-28
JP6910359B2 (ja) 2021-07-28
JP2019504067A (ja) 2019-02-14
TW201728577A (zh) 2017-08-16
CA3011880A1 (en) 2017-07-27
AU2017209935B2 (en) 2021-04-01
TWI739783B (zh) 2021-09-21
BR112018014675B1 (pt) 2023-12-19
AU2017209935A1 (en) 2018-08-09
HUE047684T2 (hu) 2020-05-28
IL260500B (en) 2021-01-31

Similar Documents

Publication Publication Date Title
TWI739783B (zh) 作為nik抑制劑的新穎的經取代氰基吲哚啉衍生物
CN109311846B (zh) 作为nik抑制剂的新的6元杂芳族取代的氰基吲哚衍生物
KR102517352B1 (ko) Nik 억제제로서의 헤테로방향족 유도체
CA3157361A1 (en) Bicyclic heterocycles as fgfr inhibitors
CN109689645B (zh) 作为nik抑制剂的氰基吲哚啉衍生物
CN107074881B (zh) 作为nik抑制剂的新的噻吩并嘧啶衍生物
CN110831940B (zh) 作为nik抑制剂的新取代的氮杂吲哚啉衍生物
RU2780577C2 (ru) Новые замещенные производные азаиндолина в качестве ингибиторов nik
HK1261385A1 (en) New substituted cyanoindoline derivatives as nik inhibitors
HK1261385B (en) New substituted cyanoindoline derivatives as nik inhibitors
EA037358B1 (ru) Новые замещённые производные цианиндолина в качестве nik-ингибиторов

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant